• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[多哥洛美皮肤科会诊中的卡波西肉瘤]

[Kaposi's sarcoma in dermatology consultations at Lome, Togo].

作者信息

Pitche P, Kombate K, Napo-Koura G, Mijiyawa M, Tchangai-Walla K

机构信息

Service de Dermatologie, Centre Hospitalier Universitaire Tokoin, Lomé, Togo.

出版信息

Med Trop (Mars). 1995;55(3):246-8.

PMID:8559021
Abstract

The purpose of this retrospective study conducted in a dermatologic out patient clinic in Lomé was to assess the epidemiologic, clinical, and prognostic profile of Kaposi's sarcoma in Togo during the 15 years period between 1980 and 1994. Only patients who had undergone serologic tests for human immunodeficiency virus (HIV) were included. There were 30 patients (27 men and 3 women) with a mean age of 35.2 years (range: 17 to 59 years). Thirteen patients were seropositive (epidemic Kaposi's sarcoma or EPK) and 17 were seronegative (endemic Kaposi's sarcoma or ENK). The mean age of patients with EPK was lower than that of patients with ENK (30.0 vs 42.3 years). Extensive (92.3%) and edematous (90%) forms and involvement of the upper extremities (66.7%), trunk (01.6%), and mucosa (92.3%) were characteristic clinical features of EPK while localized nodular forms (92.3%) were characteristic of ENK. A death was noted after 5 years of follow-up in the ENK group as compared to 12 deaths after a mean follow-up of 15.95 years in the EPK group. This study illustrates the current profile of Kaposi's sarcoma in Black Africa where HIV infection has greatly changed clinical findings and prognosis.

摘要

这项在洛美一家皮肤科门诊进行的回顾性研究旨在评估1980年至1994年这15年间多哥卡波西肉瘤的流行病学、临床及预后情况。仅纳入了接受过人类免疫缺陷病毒(HIV)血清学检测的患者。共有30例患者(27名男性和3名女性),平均年龄35.2岁(范围:17至59岁)。13例患者血清学呈阳性(流行性卡波西肉瘤或EPK),17例血清学呈阴性(地方性卡波西肉瘤或ENK)。EPK患者的平均年龄低于ENK患者(30.0岁对42.3岁)。广泛型(92.3%)和水肿型(90%)以及上肢受累(66.7%)、躯干受累(61.6%)和黏膜受累(92.3%)是EPK的特征性临床特征,而局限性结节型(92.3%)是ENK的特征性表现。ENK组在随访5年后有1例死亡,而EPK组在平均随访15.95年后有12例死亡。这项研究阐明了在黑非洲地区卡波西肉瘤的当前情况,在该地区HIV感染极大地改变了临床表现和预后。

相似文献

1
[Kaposi's sarcoma in dermatology consultations at Lome, Togo].[多哥洛美皮肤科会诊中的卡波西肉瘤]
Med Trop (Mars). 1995;55(3):246-8.
2
Kaposi's sarcoma in a hospital setting in Lomé (Togo): a study of 93 cases.多哥洛美一家医院收治的卡波西肉瘤:93例病例研究
Int J Dermatol. 2007 Oct;46 Suppl 1:42-4. doi: 10.1111/j.1365-4632.2007.03464.x.
3
Kaposi's sarcoma in HIV-negative men having sex with men.在与男性发生性行为的HIV阴性男性中的卡波西肉瘤。
AIDS. 2008 Jun 19;22(10):1163-8. doi: 10.1097/QAD.0b013e3283031a8a.
4
[Kaposi's disease].
Rev Prat. 1999 Apr 15;49(8):843-7.
5
The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.高效抗逆转录病毒治疗对254例连续性艾滋病相关卡波西肉瘤患者的疗效。
AIDS. 2009 Aug 24;23(13):1701-6. doi: 10.1097/QAD.0b013e32832d080d.
6
[Skin cancers in Togo: a 223-case series].[多哥的皮肤癌:223例病例系列]
Med Trop (Mars). 2010 Apr;70(2):169-71.
7
[AIDS-associated Kaposi's sarcoma: 22 cases].艾滋病相关卡波西肉瘤:22例
Tunis Med. 2007 Jun;85(6):494-9.
8
Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.抗疱疹病毒治疗与HIV感染患者卡波西肉瘤的风险。皇家自由医院/切尔西和威斯敏斯特医院协作组。
AIDS. 1996 Sep;10(10):1101-5.
9
[Kaposi's sarcoma during HIV infection in Morocco (apropos of 50 cases)].[摩洛哥HIV感染期间的卡波西肉瘤(关于50例病例)]
Bull Soc Pathol Exot. 2003 May;96(2):86-9.
10
[Detection of herpes virus-like DNA in various forms of Kaposi's sarcoma but not in other mesenchymal tumors or inflammatory changes in skin].[在各种类型的卡波西肉瘤中检测到疱疹病毒样DNA,但在其他间充质肿瘤或皮肤炎症变化中未检测到]
Verh Dtsch Ges Pathol. 1996;80:318-21.

引用本文的文献

1
Trends and Histopathological Patterns of Kaposi Sarcoma at The University of Benin Teaching Hospital, Benin City, Nigeria.尼日利亚贝宁城贝宁大学教学医院卡波西肉瘤的发病趋势及组织病理学模式
Oman Med J. 2018 Jul;33(4):337-341. doi: 10.5001/omj.2018.61.